Screener
Solid Biosciences Inc. SLDB Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337935
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 17,790 | 18,945 |
| Operating lease liabilities, current | 2,234 | 2,103 |
| Derivative liabilities | 4,200 | 9,200 |
| Total current liabilities | 28,584 | 33,472 |
| Non-current liabilities: | ||
| Operating lease liabilities, net of current portion | 17,921 | 19,058 |
| Total non-current liabilities | 17,921 | 19,058 |
| Total liabilities | 46,505 | 52,530 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Solid Biosciences Inc.'s total current liabilities?
- Solid Biosciences Inc. (SLDB) reported total current liabilities of $28.58M in Q2 2026.
- How has Solid Biosciences Inc.'s total current liabilities changed year-over-year?
- Solid Biosciences Inc.'s total current liabilities decreased by 4.2% year-over-year, from $29.85M to $28.58M.
- What is the long-term trend for Solid Biosciences Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Solid Biosciences Inc.'s total current liabilities has grown at a 6.5% compound annual growth rate (CAGR), from $24.48M to $33.47M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Solid Biosciences Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude